Effectiveness of HPV vaccines against genital warts in women from Valencia,Spain |
| |
| Institution: | 1. Universidad Católica de Valencia ‘San Vicente Mártir’, C/ Espartero, 7, 46007 Valencia, Spain;2. Vaccine Research Unit, Fundación para el Fomento de la Investigación Sanitaria y Biomédica (FISABIO), Avda. Catalunya 21, 46020 Valencia, Spain;3. Hospital Universitario General, Casa de la Misericordia 12, 46014 Valencia, Spain;1. University of Strathclyde, Glasgow, UK;2. Health Protection Scotland, Glasgow, UK;3. University of Edinburgh, Edinburgh, UK;4. International Prevention Research Institute, Lyon, France;5. Scottish Human Papillomavirus Reference Laboratory, Royal Infirmary of Edinburgh, UK;6. Department of Pathology, University of Edinburgh, UK;7. University of Aberdeen, Aberdeen, UK;1. Proyecto Epidemiológico Guanacaste, Fundación INCIENSA, Guanacaste, Costa Rica;2. International Agency for Research on Cancer, Lyon, France;3. Division of Cancer Epidemiology and Genetics, National Cancer Institute, Bethesda, MD, USA;4. University of California, San Francisco (UCSF), San Francisco, CA, USA;5. Information Management Services (IMS), Calverton, MD, USA;6. Center for Cancer Research, National Cancer Institute, Bethesda, MD, USA;7. Department of Pathology, University of Virginia, Charlottesville, VA, USA;8. DDL Diagnostic Laboratory, Rijswijk, The Netherlands;1. Quebec Public Health Institute, Quebec, Canada;2. Laval University Research Hospital Center, Quebec, Canada;3. Centers for Disease Control and Prevention, Atlanta, USA;1. PATH, Seattle, USA;2. PATH, Kampala, Uganda;3. National Cancer Institute, Bethesda, MD, USA;4. Uganda Virus Research Institute, UVRI-IAVI HIV Vaccine Program, Entebbe, Uganda;5. HPV Immunology Laboratory, Leidos Biomedical Research, Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA;1. Charles University in Prague—2nd Faculty of Medicine, V Úvalu 84, 150 06 Prague 5, Czech Republic;2. Institute for Clinical and Experimental Medicine, Vídeňská 1958/9, 140 21 Prague 4, Czech Republic;1. Victorian Cytology Service, PO Box 178, Carlton South, Victoria 3053, Australia;2. Cancer and Screening Unit, Australian Institute of Health and Welfare, Canberra, ACT, Australia;3. Centre for Epidemiology and Biostatistics, Melbourne School of Population and Global Health, University of Melbourne, Victoria, Australia |
| |
| Abstract: | ObjectivesTo assess the effectiveness of the HPV vaccines in preventing genital warts in young women.DesignPopulation-based study using health databases.SettingValencian Community (Spain).ParticipantsAll girls and women aged 14–19 years who were registered in the Valencian Community between January 2009 and December 2014 (n = 279,787).Main outcome measuresIncident cases of genital warts were defined as the first activation of diagnosis code ICD-9-CM 078.11 (Condyloma acuminatum) in primary care and outpatient clinics during the study period.ResultsThere were 612 cases of genital warts. The overall incidence rate was 75.8/100,000 person-years (95% CrI 69.7–81.8). There was a decrease in genital warts when female candidates to be vaccinated with quadrivalent HPV vaccine reached the age of 18 (in 2012), compared to previous years. Incidence of genital warts in unvaccinated women and those who received the bivalent vaccine was higher than in girls and women who received the quadrivalent HPV vaccine. The effectiveness of a three-dose regimen of the quadrivalent HPV vaccine was 77% (95 CrI: 66–85%), whereas that of a single dose was 61% (95 CrI: 20–87%). No effectiveness was seen with a full vaccination course with the bivalent HPV vaccine.ConclusionsThree doses of the quadrivalent HPV vaccine were effective against genital warts in our population. Moreover, with low vaccine coverage the incidence of genital warts decreased only in the vaccinated. |
| |
| Keywords: | Genital warts Human papillomavirus HPV HPV vaccine |
| 本文献已被 ScienceDirect 等数据库收录！ |
|
